Pharmacokinetic evaluation of eltoprazine
Authors:
- 27 April 2011
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 7 (6) , 775-781
Abstract
Introduction: Approvals and availability of drugs and delivery systems to treat attention-deficit/hyperactivity disorder (ADHD) have increased steadily in the last decade. The development of new pharmacological agents to treat ADHD symptoms in adults allows for both single and combination therapy for optimal efficacy. Eltoprazine hydrochloride, a serotonergic agent currently under development, is the focus of the current paper. Areas covered: This paper provides an overview of the pharmacokinetics (PK) of the non-stimulant medication eltoprazine. The PK profile of eltoprazine, based on standard PK sampling accompanied by safety monitoring, is described. A literature search and review of the studies published on eltoprazine were carried out using the PubMed database up to November 2010. Expert opinion: Although clinical studies of eltoprazine did not conclusively demonstrate its efficacy in treating pathological aggression in humans, eltoprazine has shown to be a well-tolerated drug in both healthy volunteers and patients across several indications studied thus far. More recently, the role of eltoprazine in reducing symptoms of ADHD in adults has been explored in a clinical trial. Future research may provide endophenotypical characteristics to help identify specific subgroups of patients with ADHD, who can benefit from the development of eltoprazine, to maximize efficacy while minimizing adverse reactions.Keywords
This publication has 26 references indexed in Scilit:
- Clinical Practice Guidelines for Attention-Deficit/Hyperactivity Disorder: A ReviewPostgraduate Medicine, 2010
- Understanding Attention-Deficit/Hyperactivity Disorder from Childhood to AdulthoodPostgraduate Medicine, 2010
- Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Placebo-Controlled TrialJournal of the American Academy of Child & Adolescent Psychiatry, 2009
- ADHD Subtypes and Co-Occurring Anxiety, Depression, and Oppositional-Defiant DisorderJournal of Attention Disorders, 2008
- The Laboratory School ProtocolJournal of Attention Disorders, 2006
- Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorderArchives of Disease in Childhood, 2005
- Non?stimulant medications in the treatment of ADHDEuropean Child & Adolescent Psychiatry, 2004
- An open trial of buspirone in the treatment of attention‐deficit disorderHuman Psychopharmacology: Clinical and Experimental, 2003
- Eli Lilly2003
- Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic dataJournal of Pharmacokinetics and Biopharmaceutics, 1980